Renaissance Technologies LLC Acquires 84,350 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Renaissance Technologies LLC boosted its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) by 158.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 137,500 shares of the biotechnology company’s stock after acquiring an additional 84,350 shares during the quarter. Renaissance Technologies LLC owned 0.43% of Capricor Therapeutics worth $656,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Main Street Financial Solutions LLC boosted its stake in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. Rhumbline Advisers acquired a new stake in Capricor Therapeutics during the 2nd quarter worth $147,000. Bank of New York Mellon Corp raised its position in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after purchasing an additional 200,499 shares during the period. Finally, BNP Paribas Financial Markets bought a new position in shares of Capricor Therapeutics in the 1st quarter worth $40,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Insider Buying and Selling at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.00% of the stock is currently owned by company insiders.

Capricor Therapeutics Stock Up 6.9 %

Shares of NASDAQ:CAPR opened at $19.33 on Wednesday. The business’s 50 day moving average is $6.63 and its 200 day moving average is $5.84. Capricor Therapeutics Inc has a 12-month low of $2.68 and a 12-month high of $21.98. The stock has a market cap of $618.15 million, a price-to-earnings ratio of -22.22 and a beta of 4.01.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. As a group, equities research analysts expect that Capricor Therapeutics Inc will post -1.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on CAPR. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a research note on Friday, September 20th. Maxim Group lifted their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, September 24th. Finally, Oppenheimer restated an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.60.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.